FATE THERAPEUTICS INC Proceeds from (Repayments of) Debt
FATE THERAPEUTICS INC (FATE) reported Proceeds from (Repayments of) Debt of $7.50 million for the 0-month period ending 2017-07-14, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfDebt · last filed 2020-03-02
- 2017-07-14: Proceeds from (Repayments of) Debt 0 month $7.50M.
| Period end | Proceeds from (Repayments of) Debt 0 month |
|---|---|
| 2017-07-14 | $7.50M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |